1. Rituximab depletes CD20+ B-cells via three different mechanisms: (1) antibody-dependent cellular cytotoxicity mediated by Fcγ receptors on the surface of natural killer cells, granulocytes and macrophages; (2) complement-dependent cytotoxicity; (3) induction of apoptosis.
Rituximab depletes CD20+ B-cells via three different mechanisms: (1) antibody-dependent cellular cytotoxicity mediated by Fcγ receptors on the surface of natural killer cells, granulocytes and macrophages; (2) complement-dependent cytotoxicity; (3) induction of apoptosis.
Daniel H Whittam et al. Pract Neurol 2019;19:5-20
©2019 by BMJ Publishing Group Ltd